Clients

Actinium Pharmaceuticals, Inc

Company Snapshot: Actinium Pharmaceuticals, Inc

ATNM
Last Change Volume High Low

Company Overview

Actinium Pharmaceuticals, Inc. (ATNM: NYSE MKT) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Client News

  1. Aug 9 2017 Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017
  2. Aug 2 2017 Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
  3. Jul 28 2017 Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
  4. Jul 27 2017 Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock